Tesamorelin
Worth trying, BioHarmony verdict
BioHarmony score 6.0 out of 10
Tesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for hepatic fat reduction, but cost, daily injections, reversibility, cancer contraindications, and anti-doping prohibition keep the score at 6.0-6.5/10.
Read full reportWhat is Tesamorelin?
Tesamorelin is a prescription peptide that mimics growth hormone-releasing hormone and stimulates the pituitary GHRH receptor. Instead of injecting growth hormone directly, tesamorelin amplifies endogenous pulsatile GH release and raises downstream IGF-1. The practical result is a selective lipolytic signal that reduces visceral adipose tissue in the FDA-approved HIV lipodystrophy population while largely preserving subcutaneous fat.
From the BioHarmony report, reviewed Sep 19, 2026.
Saved on this device only.
How it is thought to work
Binds pituitary GHRH receptors and amplifies endogenous pulsatile GH release, raising IGF-1 while preserving somatostatin-mediated negative feedback.
Safety watch-outs
- Severe edema or carpal tunnel symptoms
- Fasting glucose drift upward
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (4)
Attributed viewpoints, separate from primary research.
- Peptides to Promote Cellular Health Dr. Suzanne Ferree,
- My Top Peptide Stack for Mental Clarity & Muscle Repair Alex Kikel,
- The Tesamorelin Masterclass | The Complete User's Guide (2026) Hunter Williams,
- Tesamorelin vs Ipamorelin: In-Depth Comparison Jay Campbell,
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
FDA-approved tesamorelin is available as two formulations that the label states are not substitutable, Egrifta WR and Egrifta SV, for reducing excess abdominal fat in adults with HIV and lipodystrophy; neither is indicated for weight-loss management.
Primary sources
- Egrifta SV (tesamorelin) prescribing information DailyMed, U.S. National Library of Medicine,
- Egrifta WR (tesamorelin) prescribing information DailyMed, U.S. National Library of Medicine,
Related peptides for weight & metabolic
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
- 5.8CagrilintideCagrilintide (AM833) is a long-acting amylin receptor analogue that drove about 11.8 percent weight loss as monotherapy at 68 weeks in REDEFINE 1 per Garvey 2025, with…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.